Allergan has acquired Chase Pharmaceuticals Company for a payment of 125
million dollars with certain adjustments and extra potential regulatory related to
Chase’s lead compound. Chase has closed by 24 million dollars in funding will
approx 22 million dollars through B series led by new health care investors,
Edmond de Rothschild investment partners, brain trust accelerator fund and Cipla
ventures. Allergan upfront payment of 125 million dollars and will also be on the
hook for added regulatory. According to Mr. David the chief research and
upgrading managerial of Allergan company said that , ‘ this achievement will
connect a novel phase three ready program for the disease to the company’s
portfolio and construct on our promises and commitment to enlarging inventive
approaches to perk up the lives of billion of people suffering from this infirmity’.
For expansion of its CNS R&D pipeline Allergan has taken this step to acquire Chase
pharmaceuticals and this deal comprises of added potential related to chase’s
lead compound and many other backup compounds. Chase president Douglas
Ingram said that it’s in actuality thrilled, that Allergan has the strapping clinical
worth of the expansion programs.
About Chase Pharmaceuticals
It is a biopharmaceutical company which totally focuses on the overall
development of improved treatments for disorders related to neurodegenerative.
The company was founded by Thomas Chase and is totally focused on
manufacturing, developing and commercializing branded devices and biologic
products all around the world. It comes under the leading brands and made best
products for eye care, medical aesthetics, women’s health, urology and much
more. Allegan is totally committed to working with healthcare providers and
patients all around the world to offer meaningful treatments.